Pfizer wins SUTENT® patent case in Delaware District Court
Pfizer announced the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT® (sunitinib malate) capsules. This decision affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through 2021. October 23, 2014